November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Welcoming Carlos Del Fresno and Marta Dueñas Porta to the next edition of Richi Entrepreneurs
Nov 12, 2024, 00:31

Welcoming Carlos Del Fresno and Marta Dueñas Porta to the next edition of Richi Entrepreneurs

Richi Entrepreneurs shared a post on LinkedIn:

” We are excited to welcome Carlos Del Fresno to the next edition of Richi Entrepreneurs. As the recipient of the prestigious Pfizer FoundationITEMAS Award, Carlos will join us in Boston to advance his project, PolyFIL, focused on innovative liquid biopsy for colon health.

We are also thrilled to announce that Marta Dueñas Porta, last year’s recipient of the same award, will be joining us as well. Marta’s startup, BlaDimir, is developing a device for bladder cancer diagnosis.

A huge thank you to Pfizer Foundation and ITEMAS for supporting groundbreaking initiatives like this and for your collaboration in empowering innovators.”

Carlos Del Fresno

More posts featuring Richi Entrepreneurs.

Carlos Del Fresno is the Co-Director of the Innate Immune Response Group and Head of the Immunomodulation Lab at the Hospital La Paz Institute for Health Research (IdiPAZ). His research focuses on immunology, particularly in cancer and infectious diseases, working across multiple labs, including one in Italy. He has expertise in quantitative PCR, confocal microscopy, and multiparametric flow cytometry, including full-spectrum approaches, applied to studies involving human samples and mouse models.

Marta Dueñas leads the liquid biopsy project for genitourinary tumors in the Molecular Biology Unit at CIEMAT-Fundación de Investigación Hospital 12 de Octubre in Madrid. Her research focuses on bladder cancer, with expertise in identifying and validating biomarkers for diagnostics and predicting response to BCG and immunotherapy in both tissue and urine samples. She is also studies the tumor microenvironment (TME) to better understand bladder cancer development, progression, and therapy resistance.